ExonHit and Allergan expand collaboration
This article was originally published in Scrip
Executive Summary
French company ExonHit Therapeutics and Allergan have expanded and extended an agreement to develop drugs for neurodegenerative and eye diseases and pain. Financial details have not been disclosed. Allergan has exercised its option to extend the deal until December 2011 and it now includes the discovery of antibodies for eye disorders based on epitope technology. The agreement expands Allergan's rights to sublicense potential compounds. ExonHit will receive up-front payments and development and sales-based milestones as well as royalties on future sales. EHT/AGN 0001, the most advanced compound from the collaboration, is completing Phase I trials for pain. Other compounds are in preclinical testing for pain, ophthalmology and neurodegenerative disease indications. The companies initiated the deal in December 2002 and have renewed it several times.
You may also be interested in...
Innovation not M&A to drive Bayer growth in LatAm
Laura Gonz�lez-Molero will be celebrating her first anniversary as President of Bayer HealthCare Pharmaceuticals, Latin America this month. With Bayer posting total sales of €1.05bnin Latin America in 2014, up 13% over 2013, Ms Gonz�lez-Molero should be pleased with a successful inaugural year. Resolute in her belief that innovation, "part of Bayer's DNA," will determine the company's long-term success in Latin America, rather than growth through acquisition, Ms Gonz�lez-Molero talks to Scrip about her personal ambitions for the company and the region.
2010 Scrip 100 - Is Anvisa a friend of innovators?
A decade since its formation Anvisa, Brazil's medicines regulator, has shaken up the country's framework for ensuring drug quality. Yet the agency's approaches to drug pricing and registration have left some multinationals wanting, reports Sita Shah.
Elan raises $1.5 billion
Elan is raising $1.5 billion in bonds to refinance its existing debt and for general corporate purposes, it says.